Increasing FDA Scrutiny of Foreign Clinical Data: Implications for Biotechs
The FDA’s September 3, 2026 statement on foreign clinical research is primarily about clinical-trial oversight, data reliability, informed consent, and the agency’s ability to evaluate evidence submitted in support of regulatory decisions. It is not a cybersecurity announcement, and it should not be treated as one.
It does, however, raise practical questions for those in clinical stage biotech organizations whose remit is overseeing and operating IT and Cyber capabilities.
GCP depends not only on protocols, investigators, and clinical procedures. It also depends on the systems used to collect, process, store, transmit, and review clinical data; the vendors operating those systems; and the controls that preserve the reliability and availability of trial records.
The question is not whether a foreign study is inherently unreliable or whether every clinical partner must meet an identical technology standard. Rather, it is whether the sponsor can demonstrate that the trial was conducted appropriately and that the resulting data are reliable, traceable, protected, and available for review.
That expectation inherently cuts across functional boundaries. Effective sponsor oversight therefore depends on close collaboration among Clinical, Quality, Regulatory, and Technology and Cybersecurity teams, each bringing a different perspective to the systems, processes, data, and third parties supporting the trial. This cross-functional governance becomes an important supporting element of the sponsor’s broader responsibilities under GCP.
Key takeaways
FDA’s increased focus on foreign clinical data should prompt biotech technology leaders to revisit how clinical data and records are created, modified, transferred, stored, retained, and retrieved across the trial lifecycle.
Develop a clear, documented understanding of the clinical partner ecosystem, including key systems, vendors, data flows, trust boundaries, system interfaces, and chain of custody for critical clinical records.
Reassess vendor risk with greater attention to the specific cybersecurity, data integrity, access, retention, and operational controls supporting clinical trial activities.
Partner with Quality and Clinical Operations on key vendor assessments and audits to confirm that systems and processes appropriately support requirements tied to the protocol, informed consent, data integrity, and applicable regulatory obligations.
A security questionnaire, SOC report, or certification is not sufficient on its own. Sponsors should understand whether the specific systems and processes used to support the trial are fit for purpose and appropriately controlled.
Apply a risk-based approach. The level of validation, monitoring, documentation, and assurance should be proportionate to the importance of the system, the sensitivity of the data, and the potential impact on subject safety, data integrity, or regulatory decision-making.
Technology teams should work closely with Clinical Operations, Quality, Regulatory, Privacy, and Legal to identify the systems, vendors, data flows, controls, and evidence that are most important to the integrity and defensibility of the trial.
Why the FDA announcement is important
The FDA is not saying that foreign clinical research is inherently unreliable. The agency recognizes that many foreign research institutions produce high-quality clinical data. The concern is that studies conducted outside the United States can create additional challenges for FDA when it comes to inspecting sites, accessing records, and independently evaluating the evidence a sponsor ultimately relies upon.
That is the impetus for the announcement. When clinical research is conducted across jurisdictions, the FDA may have less direct access to investigators, facilities, source records, and supporting systems. The burden therefore falls more heavily on the sponsor to demonstrate that the data is reliable, traceable, and supported by appropriate oversight.
For technology teams, that makes inspection readiness partly a systems and records issue. If clinical data cannot be accessed, audit trails are incomplete, system changes are poorly documented, or a vendor cannot produce supporting records, it becomes harder for the sponsor to demonstrate how the evidence was generated, maintained, and controlled.
The foreign context also introduces practical questions around where records are stored, who controls the systems that hold them, whether data can be exported in a usable format, whether access can be maintained across jurisdictions, and what happens to the records when a study or vendor relationship ends. These issues can be driven by regulatory, contractual, operational, or technical constraints.
Finally, this announcement also aligns with ICH E6(R3), which places greater emphasis on risk-based quality management, sponsor oversight, data governance, and the appropriate use of computerized systems throughout the clinical-trial lifecycle.
What questions biotechs should be considering
What systems are used to collect, process, store, or transmit clinical data?
Which records are considered source records, and where are they maintained?
Who can access, create, modify, approve, or delete records?
Are user accounts unique, role-based, and removed promptly when access is no longer needed?
Are audit trails enabled, retained, and available for review?
Can the sponsor determine what changed, when it changed, and who made the change?
How are electronic consent records protected and retrieved?
How are data transferred between sites, CROs, laboratories, sponsors, and other vendors?
Where are systems and data hosted, and could jurisdictional restrictions affect access?
How are backups, disaster recovery, and business continuity handled?
What happens if a critical vendor experiences an outage, security incident, or loss of records?
How are security incidents, privacy incidents, and data-integrity concerns reported to the sponsor?
Can the vendor produce relevant records and supporting evidence within the time required for an audit or inspection?
What happens to the data and records when the study ends or the vendor relationship terminates?
Why a generic vendor questionnaire falls short
A conventional IT vendor assessment may ask whether a CRO or clinical technology provider has MFA, endpoint protection, vulnerability management, incident-response procedures, or a security certification. Those questions can be useful, but they do not establish that the specific clinical process is operating appropriately.
For example, a vendor may have strong enterprise security controls while:
using a clinical application with limited audit-trail functionality;
relying on shared accounts at some sites;
retaining records for a shorter period than the sponsor requires;
lacking a clear process for exporting study data and metadata;
restricting sponsor access to records held in its systems;
failing to document changes to a critical configuration;
using subcontractors that are not visible to the sponsor; or
having no practical way to produce records during an inspection.
The better question is not simply whether the vendor has a mature security program, it is:
What does the sponsor need to be confident is true about the systems and processes supporting this trial?
Answering that question may require a joint assessment involving Clinical Operations, Quality, Regulatory, Privacy, Legal, and Technology. The result should identify the critical systems, data flows, control owners, known limitations, dependencies, and evidence that may be needed later.
Practical areas to review
System inventory and data flows
The sponsor should know which systems support the trial and how data moves between them. This may include electronic data capture, electronic trial master files, electronic consent, randomization and trial-supply systems, safety databases, laboratory systems, imaging platforms, wearable devices, patient-facing applications, identity providers, collaboration tools, and data warehouses.
The inventory should also account for systems operated by CROs, sites, laboratories, and subcontractors. A sponsor may not administer those systems directly, but it may still depend on them for regulated records or critical trial data.
Access and identity management
Access should be based on role and need. Teams should understand how accounts are created, approved, reviewed, changed, and removed. Particular attention may be needed for privileged users, site personnel, CRO staff, temporary workers, and vendor support personnel.
The objective is not merely to confirm that MFA exists. It is to determine whether the right people have the right access for the right period and whether the sponsor can demonstrate that access was controlled.
Audit trails and data integrity
Audit trails can help establish how records were created and changed. Teams should understand whether audit trails are enabled, what events they capture, how long they are retained, who can review them, and whether they can be exported or provided during an inspection.
Audit trails are not a substitute for sound clinical processes, but missing or inaccessible audit information can make it harder to investigate discrepancies or demonstrate the reliability of the data.
Availability, backup, and recovery
A system that is unavailable during a critical trial activity can affect data collection, safety reporting, site operations, or participant interactions. Backup and recovery arrangements should therefore be considered in relation to the clinical process, not only the vendor’s general disaster-recovery program.
Questions should include whether backups are tested, how quickly systems can be restored, what data may be lost after an incident, and how the sponsor will continue operations if a vendor is unavailable.
Incident response and escalation
Contracts and operating procedures should make clear how the sponsor will be notified of security incidents, privacy incidents, system outages, suspected data manipulation, or other events that could affect the trial.
The relevant issue is not only whether the vendor has an incident-response plan. It is whether the sponsor will receive timely and sufficiently detailed information to assess potential effects on participants, trial conduct, data integrity, reporting obligations, and regulatory submissions.
Records retention and retrieval
Clinical records may need to be retained for long periods and retrieved in a form that remains usable. The sponsor should understand who owns the records, who controls access, how records are preserved, and what happens when a vendor relationship ends.
A contract that says records will be retained is not enough if the sponsor cannot later obtain the records, associated metadata, audit trails, or other evidence needed to interpret them.
Change management and system updates
Changes to a clinical system, integration, configuration, or workflow can affect data collection and trial conduct. Technology teams should understand how changes are assessed, approved, tested, documented, and communicated to the relevant clinical and quality stakeholders.
This is particularly important when vendors make changes to cloud platforms or software that the sponsor does not directly control.
What this means for lean biotech teams
A small biotech may not have a large internal IT, cybersecurity, or quality organization. That does not eliminate the need to understand the technology supporting the trial. It makes prioritization more important.
The company does not need to build every control internally or impose the same requirements on every vendor. It does need to identify the systems and processes that could materially affect participant protection, data integrity, privacy, trial continuity, or inspection readiness.
A practical approach may be to:
Identify the clinical processes and records that are most important to the trial.
Map the systems, vendors, sites, and data flows supporting those processes.
Determine which technology and cybersecurity controls are relevant to each system.
Confirm who owns each control and what evidence is available.
Document gaps, compensating controls, and decisions.
Reassess the environment when the trial, vendor, system, or regulatory context changes.
